CN1105577C - 用于增加骨质量的甲状旁腺素和拉洛西芬 - Google Patents

用于增加骨质量的甲状旁腺素和拉洛西芬 Download PDF

Info

Publication number
CN1105577C
CN1105577C CN94108159A CN94108159A CN1105577C CN 1105577 C CN1105577 C CN 1105577C CN 94108159 A CN94108159 A CN 94108159A CN 94108159 A CN94108159 A CN 94108159A CN 1105577 C CN1105577 C CN 1105577C
Authority
CN
China
Prior art keywords
raloxifene
pth
bone
parathyroid hormone
bone mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94108159A
Other languages
English (en)
Chinese (zh)
Other versions
CN1105882A (zh
Inventor
J·M·霍克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1105882A publication Critical patent/CN1105882A/zh
Application granted granted Critical
Publication of CN1105577C publication Critical patent/CN1105577C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN94108159A 1993-07-22 1994-07-21 用于增加骨质量的甲状旁腺素和拉洛西芬 Expired - Fee Related CN1105577C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9648093A 1993-07-22 1993-07-22
US096480 1993-07-22
US096,480 1993-07-22

Publications (2)

Publication Number Publication Date
CN1105882A CN1105882A (zh) 1995-08-02
CN1105577C true CN1105577C (zh) 2003-04-16

Family

ID=22257534

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94108159A Expired - Fee Related CN1105577C (zh) 1993-07-22 1994-07-21 用于增加骨质量的甲状旁腺素和拉洛西芬

Country Status (30)

Country Link
US (1) US5510370A (US06906086-20050614-C00008.png)
EP (1) EP0635270B1 (US06906086-20050614-C00008.png)
JP (1) JPH0769920A (US06906086-20050614-C00008.png)
KR (1) KR100306852B1 (US06906086-20050614-C00008.png)
CN (1) CN1105577C (US06906086-20050614-C00008.png)
AT (1) ATE189959T1 (US06906086-20050614-C00008.png)
AU (1) AU686628B2 (US06906086-20050614-C00008.png)
BR (1) BR9402902A (US06906086-20050614-C00008.png)
CA (1) CA2128376A1 (US06906086-20050614-C00008.png)
CY (1) CY2192B1 (US06906086-20050614-C00008.png)
CZ (1) CZ289648B6 (US06906086-20050614-C00008.png)
DE (1) DE69423146T2 (US06906086-20050614-C00008.png)
DK (1) DK0635270T3 (US06906086-20050614-C00008.png)
ES (1) ES2142380T3 (US06906086-20050614-C00008.png)
GR (1) GR3033492T3 (US06906086-20050614-C00008.png)
HK (1) HK1013800A1 (US06906086-20050614-C00008.png)
HU (1) HU219382B (US06906086-20050614-C00008.png)
IL (1) IL110350A (US06906086-20050614-C00008.png)
MY (1) MY124311A (US06906086-20050614-C00008.png)
NO (1) NO942708L (US06906086-20050614-C00008.png)
NZ (2) NZ264027A (US06906086-20050614-C00008.png)
PE (1) PE14595A1 (US06906086-20050614-C00008.png)
PH (1) PH30686A (US06906086-20050614-C00008.png)
PL (1) PL304348A1 (US06906086-20050614-C00008.png)
PT (1) PT635270E (US06906086-20050614-C00008.png)
RU (1) RU2155042C2 (US06906086-20050614-C00008.png)
SI (1) SI0635270T1 (US06906086-20050614-C00008.png)
TW (1) TW303299B (US06906086-20050614-C00008.png)
YU (1) YU49170B (US06906086-20050614-C00008.png)
ZA (1) ZA945249B (US06906086-20050614-C00008.png)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5578613A (en) * 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5502074A (en) * 1994-08-22 1996-03-26 Eli Lilly And Company Benzothiophenes for bone healing and fracture repair
WO1996007416A1 (en) * 1994-09-09 1996-03-14 The Procter & Gamble Company Estrogens and parathyroid hormone for treating osteoporosis
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
JPH10513470A (ja) * 1995-02-06 1998-12-22 イーライ・リリー・アンド・カンパニー Ｉｌ−６の効果を阻害する方法
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
AU761274B2 (en) * 1996-01-29 2003-05-29 Schering Aktiengesellschaft Pharmaceutical combination preparation that consists of LHRH-analogues and antiestrogens for treating gynecological disorders
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US20020094951A1 (en) * 1997-07-22 2002-07-18 Noboru Horiuchi Dental remedies containing pth
AU9682098A (en) * 1997-10-14 1999-05-03 Eli Lilly And Company Method of building and maintaining bone
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
WO2000019823A1 (en) * 1998-10-07 2000-04-13 The Board Of Trustees Of The University Of Arkansas Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof
WO2000028982A2 (en) 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US20040214889A1 (en) * 1999-07-31 2004-10-28 Smithkline Beecham Corporation Calcilytic compounds
WO2001022093A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
WO2002030264A2 (en) * 2000-10-10 2002-04-18 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
CN100548283C (zh) * 2001-11-29 2009-10-14 Gtx公司 雄激素剥夺引起的骨质疏松症的预防和治疗
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
US20040063692A1 (en) * 2002-06-13 2004-04-01 Wyeth Bazedoxifene treatment regimens
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
AU2005206137A1 (en) * 2004-01-13 2005-08-04 Wyeth Treatment of aromatase inhibitor therapy-related osteoporosis
US7556821B2 (en) * 2004-05-13 2009-07-07 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
EP1843783B1 (en) * 2005-01-25 2012-05-30 MicroCHIPS, Inc. Control of drug release by transient modification of local microenvironments
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
US7691105B2 (en) * 2005-09-26 2010-04-06 Depuy Spine, Inc. Tissue augmentation, stabilization and regeneration technique
US20070088436A1 (en) 2005-09-29 2007-04-19 Matthew Parsons Methods and devices for stenting or tamping a fractured vertebral body
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
BRPI0618469A2 (pt) * 2005-11-10 2011-08-30 Univ Michigan Tech hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto
US20070168041A1 (en) * 2006-01-17 2007-07-19 Sudhakar Kadiyala Method and instruments for intervertebral disc augmentation through a pedicular approach
ES2666650T3 (es) 2006-12-29 2018-05-07 OstéoQC Inc. Métodos para alterar el crecimiento óseo mediante la administración de antagonista o agonista de sost o wise
ES2381639T3 (es) * 2007-04-13 2012-05-30 Kuros Biosurgery Ag Sellante polimérico para tejidos
US8241294B2 (en) * 2007-12-19 2012-08-14 Depuy Spine, Inc. Instruments for expandable corpectomy spinal fusion cage
US8241363B2 (en) 2007-12-19 2012-08-14 Depuy Spine, Inc. Expandable corpectomy spinal fusion cage
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8876905B2 (en) * 2009-04-29 2014-11-04 DePuy Synthes Products, LLC Minimally invasive corpectomy cage and instrument
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2011128424A1 (en) * 2010-04-16 2011-10-20 Novartis Ag Methods and compositions for improving implant osseointegration
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
JP6683628B2 (ja) * 2014-06-04 2020-04-22 シーダーズ−サイナイ メディカル センター 脊椎圧迫骨折の非外科的修復のための方法
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197514A1 (en) * 1985-04-04 1986-10-15 The General Hospital Corporation Pharmaceutical composition for use in increasing bone mass
EP0584952A1 (en) * 1992-07-28 1994-03-02 Eli Lilly And Company Improvements in or relating to benzothiophenes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197514A1 (en) * 1985-04-04 1986-10-15 The General Hospital Corporation Pharmaceutical composition for use in increasing bone mass
EP0584952A1 (en) * 1992-07-28 1994-03-02 Eli Lilly And Company Improvements in or relating to benzothiophenes

Also Published As

Publication number Publication date
SI0635270T1 (en) 2000-08-31
PH30686A (en) 1997-09-16
CA2128376A1 (en) 1995-01-23
NZ264027A (en) 1996-03-26
CZ173394A3 (en) 1995-04-12
ATE189959T1 (de) 2000-03-15
HU219382B (en) 2001-03-28
HU9402157D0 (en) 1994-09-28
ES2142380T3 (es) 2000-04-16
IL110350A0 (en) 1994-10-21
NO942708L (no) 1995-01-23
AU686628B2 (en) 1998-02-12
YU46794A (sh) 1997-03-07
RU94027680A (ru) 1996-11-10
NO942708D0 (no) 1994-07-19
DE69423146T2 (de) 2000-09-21
CZ289648B6 (cs) 2002-03-13
KR950002785A (ko) 1995-02-16
MY124311A (en) 2006-06-30
US5510370A (en) 1996-04-23
KR100306852B1 (ko) 2001-11-30
PL304348A1 (en) 1995-01-23
HK1013800A1 (en) 1999-09-10
GR3033492T3 (en) 2000-09-29
DK0635270T3 (da) 2000-06-05
CY2192B1 (en) 2002-11-08
CN1105882A (zh) 1995-08-02
YU49170B (sh) 2004-05-12
BR9402902A (pt) 1995-04-11
EP0635270B1 (en) 2000-03-01
RU2155042C2 (ru) 2000-08-27
PE14595A1 (es) 1995-06-01
PT635270E (pt) 2000-07-31
EP0635270A1 (en) 1995-01-25
IL110350A (en) 2002-02-10
DE69423146D1 (de) 2000-04-06
HUT67945A (en) 1995-05-29
TW303299B (US06906086-20050614-C00008.png) 1997-04-21
AU6757794A (en) 1995-02-02
JPH0769920A (ja) 1995-03-14
NZ280040A (en) 1997-06-24
ZA945249B (en) 1996-01-18

Similar Documents

Publication Publication Date Title
CN1105577C (zh) 用于增加骨质量的甲状旁腺素和拉洛西芬
AU645874B2 (en) Treatment for osteoporosis using growth hormone release factor (GRF) in combination with parathyroid hormone (PTH)
Arens et al. Influence of materials for fixation implants on local infection: an experimental study of steel versus titanium DCP in rabbits
JP3053116B2 (ja) 医薬組成物
CN1078073C (zh) 二膦酸盐在矫形假体移植后在抑制骨再吸收中的应用
JP2009508820A (ja) 副甲状腺ホルモンアナログおよび使用法
JP3771280B2 (ja) オステオポローシスの治療方法およびそのための組成物
Evans et al. Paget's disease of bone: the effect of stopping long term human calcitonin and recommendations for future treatment
EP2502632B1 (en) Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis
US20040242489A1 (en) Method for improving stability of a bone-connecting implant
Murakami et al. Calcium hydroxide ameliorates tobramycin toxicity in cultured chick tibiae
CN113069534B (zh) Igsf10在制备骨组织再生产品中的用途
Junior Impact of Anti-Resorptive Treatment on Bones Recovering From Disuse
SHANDS et al. PROGRESS IN ORTHOPEDIC SURGERY FOR 1946 A Review Prepared by an Editorial Board of the American Academy of Orthopaedic Surgeons: XXI. RESEARCH
UA69145A (en) Method for treating fractures of long bones
EP1767213A2 (en) Method for improving stability of a bone-connecting implant

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee